In vitro activity of arbekacin against clinical isolates of Staphylococcus species and gram-negative bacilli

Jonghan Lee, Chang Ki Kim, Kyoung Ho Roh, Hyukmin Lee, Jong Hwa Yum, DongEun Yong, Kyungwon Lee, Yunsop Chong

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) and some gram-negative bacilli are very prevalent nosocomial pathogens, commonly causing mixed infections, and are often resistant to multiple drugs. Arbekacin is an aminoglycoside used for the treatment of MRSA infections, but is also active against some gram-negative bacilli. The aim of this study was to determine in vitro activity of arbekacin against recent clinical isolates of staphylococci and gram-negative bacilli. Materials and METHODS: The strains were isolated from clinical specimens of patients at Severance Hospital in 2003. Antimicrobial susceptibility was tested by the Clinical and Laboratory Standards Institute agar dilution method. The following arbekacin breakpoints were used: susceptible, </=4 microg/mL; and resistant, >/=16 microg/mL . RESULTS: All isolates of staphylococci tested were inhibited by </=4 microg/mL of arbekacin, regardless of their methicillin susceptibility. The MIC90s of arbekacin, 1-4 microg/mL, were 8->32-fold and >32-128-fold lower than those of amikacin and gentamicin, respectively. The resistance rates of MRSA, methicillin-susceptible S. aureus, methicillin-resistant coagulase-negative staphylococci (CNS) and methicillin-susceptible CNS were 0% to arbekacin, 0-54% to amikacin, and 24-79% to gentamicin. The MIC90s of arbekacin for Escherichia coli and Citrobacter freundii, 1 microg/mL and 16 microg/mL, were 2-4-fold and 8-16-fold lower than those of amikacin and gentamicin, respectively. However, The MIC90s of arbekacin for other species of gram-negative bacilli, 64->128 microg/mL, were similar to those of other aminoglycosides. CONCLUSIONS: Arbekacin may be a useful alternative to glycopeptides for the treatment of monomicrobial methicillin-resistant staphylococcal infections, as well as mixed infections with gram-negative bacilli, as most isolates of E. coli, C. freundii and some other gram-negative bacilli were also susceptible to arbekacin.

Original languageEnglish
Pages (from-to)292-297
Number of pages6
JournalThe Korean journal of laboratory medicine
Volume27
Issue number4
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Bacilli
Methicillin
Staphylococcus
Bacillus
Methicillin-Resistant Staphylococcus aureus
Amikacin
Gentamicins
Citrobacter freundii
Coagulase
Aminoglycosides
Coinfection
Escherichia coli
Staphylococcal Infections
Methicillin Resistance
Glycopeptides
In Vitro Techniques
habekacin
Pathogens
Dilution
Agar

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Lee, Jonghan ; Kim, Chang Ki ; Roh, Kyoung Ho ; Lee, Hyukmin ; Yum, Jong Hwa ; Yong, DongEun ; Lee, Kyungwon ; Chong, Yunsop. / In vitro activity of arbekacin against clinical isolates of Staphylococcus species and gram-negative bacilli. In: The Korean journal of laboratory medicine. 2007 ; Vol. 27, No. 4. pp. 292-297.
@article{a2a1d2b54cdd47d6aeaad4c923fb9626,
title = "In vitro activity of arbekacin against clinical isolates of Staphylococcus species and gram-negative bacilli",
abstract = "BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) and some gram-negative bacilli are very prevalent nosocomial pathogens, commonly causing mixed infections, and are often resistant to multiple drugs. Arbekacin is an aminoglycoside used for the treatment of MRSA infections, but is also active against some gram-negative bacilli. The aim of this study was to determine in vitro activity of arbekacin against recent clinical isolates of staphylococci and gram-negative bacilli. Materials and METHODS: The strains were isolated from clinical specimens of patients at Severance Hospital in 2003. Antimicrobial susceptibility was tested by the Clinical and Laboratory Standards Institute agar dilution method. The following arbekacin breakpoints were used: susceptible, /=16 microg/mL . RESULTS: All isolates of staphylococci tested were inhibited by 32-fold and >32-128-fold lower than those of amikacin and gentamicin, respectively. The resistance rates of MRSA, methicillin-susceptible S. aureus, methicillin-resistant coagulase-negative staphylococci (CNS) and methicillin-susceptible CNS were 0{\%} to arbekacin, 0-54{\%} to amikacin, and 24-79{\%} to gentamicin. The MIC90s of arbekacin for Escherichia coli and Citrobacter freundii, 1 microg/mL and 16 microg/mL, were 2-4-fold and 8-16-fold lower than those of amikacin and gentamicin, respectively. However, The MIC90s of arbekacin for other species of gram-negative bacilli, 64->128 microg/mL, were similar to those of other aminoglycosides. CONCLUSIONS: Arbekacin may be a useful alternative to glycopeptides for the treatment of monomicrobial methicillin-resistant staphylococcal infections, as well as mixed infections with gram-negative bacilli, as most isolates of E. coli, C. freundii and some other gram-negative bacilli were also susceptible to arbekacin.",
author = "Jonghan Lee and Kim, {Chang Ki} and Roh, {Kyoung Ho} and Hyukmin Lee and Yum, {Jong Hwa} and DongEun Yong and Kyungwon Lee and Yunsop Chong",
year = "2007",
month = "1",
day = "1",
doi = "10.3343/kjlm.2007.27.4.292",
language = "English",
volume = "27",
pages = "292--297",
journal = "Annals of Laboratory Medicine",
issn = "2234-3806",
publisher = "Seoul National University",
number = "4",

}

In vitro activity of arbekacin against clinical isolates of Staphylococcus species and gram-negative bacilli. / Lee, Jonghan; Kim, Chang Ki; Roh, Kyoung Ho; Lee, Hyukmin; Yum, Jong Hwa; Yong, DongEun; Lee, Kyungwon; Chong, Yunsop.

In: The Korean journal of laboratory medicine, Vol. 27, No. 4, 01.01.2007, p. 292-297.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro activity of arbekacin against clinical isolates of Staphylococcus species and gram-negative bacilli

AU - Lee, Jonghan

AU - Kim, Chang Ki

AU - Roh, Kyoung Ho

AU - Lee, Hyukmin

AU - Yum, Jong Hwa

AU - Yong, DongEun

AU - Lee, Kyungwon

AU - Chong, Yunsop

PY - 2007/1/1

Y1 - 2007/1/1

N2 - BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) and some gram-negative bacilli are very prevalent nosocomial pathogens, commonly causing mixed infections, and are often resistant to multiple drugs. Arbekacin is an aminoglycoside used for the treatment of MRSA infections, but is also active against some gram-negative bacilli. The aim of this study was to determine in vitro activity of arbekacin against recent clinical isolates of staphylococci and gram-negative bacilli. Materials and METHODS: The strains were isolated from clinical specimens of patients at Severance Hospital in 2003. Antimicrobial susceptibility was tested by the Clinical and Laboratory Standards Institute agar dilution method. The following arbekacin breakpoints were used: susceptible, /=16 microg/mL . RESULTS: All isolates of staphylococci tested were inhibited by 32-fold and >32-128-fold lower than those of amikacin and gentamicin, respectively. The resistance rates of MRSA, methicillin-susceptible S. aureus, methicillin-resistant coagulase-negative staphylococci (CNS) and methicillin-susceptible CNS were 0% to arbekacin, 0-54% to amikacin, and 24-79% to gentamicin. The MIC90s of arbekacin for Escherichia coli and Citrobacter freundii, 1 microg/mL and 16 microg/mL, were 2-4-fold and 8-16-fold lower than those of amikacin and gentamicin, respectively. However, The MIC90s of arbekacin for other species of gram-negative bacilli, 64->128 microg/mL, were similar to those of other aminoglycosides. CONCLUSIONS: Arbekacin may be a useful alternative to glycopeptides for the treatment of monomicrobial methicillin-resistant staphylococcal infections, as well as mixed infections with gram-negative bacilli, as most isolates of E. coli, C. freundii and some other gram-negative bacilli were also susceptible to arbekacin.

AB - BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) and some gram-negative bacilli are very prevalent nosocomial pathogens, commonly causing mixed infections, and are often resistant to multiple drugs. Arbekacin is an aminoglycoside used for the treatment of MRSA infections, but is also active against some gram-negative bacilli. The aim of this study was to determine in vitro activity of arbekacin against recent clinical isolates of staphylococci and gram-negative bacilli. Materials and METHODS: The strains were isolated from clinical specimens of patients at Severance Hospital in 2003. Antimicrobial susceptibility was tested by the Clinical and Laboratory Standards Institute agar dilution method. The following arbekacin breakpoints were used: susceptible, /=16 microg/mL . RESULTS: All isolates of staphylococci tested were inhibited by 32-fold and >32-128-fold lower than those of amikacin and gentamicin, respectively. The resistance rates of MRSA, methicillin-susceptible S. aureus, methicillin-resistant coagulase-negative staphylococci (CNS) and methicillin-susceptible CNS were 0% to arbekacin, 0-54% to amikacin, and 24-79% to gentamicin. The MIC90s of arbekacin for Escherichia coli and Citrobacter freundii, 1 microg/mL and 16 microg/mL, were 2-4-fold and 8-16-fold lower than those of amikacin and gentamicin, respectively. However, The MIC90s of arbekacin for other species of gram-negative bacilli, 64->128 microg/mL, were similar to those of other aminoglycosides. CONCLUSIONS: Arbekacin may be a useful alternative to glycopeptides for the treatment of monomicrobial methicillin-resistant staphylococcal infections, as well as mixed infections with gram-negative bacilli, as most isolates of E. coli, C. freundii and some other gram-negative bacilli were also susceptible to arbekacin.

UR - http://www.scopus.com/inward/record.url?scp=55449113049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55449113049&partnerID=8YFLogxK

U2 - 10.3343/kjlm.2007.27.4.292

DO - 10.3343/kjlm.2007.27.4.292

M3 - Article

VL - 27

SP - 292

EP - 297

JO - Annals of Laboratory Medicine

JF - Annals of Laboratory Medicine

SN - 2234-3806

IS - 4

ER -